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It hasbecome evidentthat theCD4 subset of lymphocytes isaheterogeneous col-
lection of cells with multiple phenotypes and functions (1-3) . Recently, CD4+ lym-
phocytes have been subdivided into reciprocal subsets based on their expression of
unique isoforms of the leucocyte common antigen (LCA)1/T200 family of antigens
(CD45/CD45R) (4-6) and the CDw29 (4B4) antigen (7). CD4+CDw29+ cells (in
fact, CDw29h`gh) provide strong helper function for B cell Ig production, respond
maximally to recall antigens (7), and induce CD8 cells to exert class I MHC-re-
stricted cytotoxicity (8). TheCD4+CD45R +CDw29- (in fact, CDw291°"') cells, in
contrast, can induce CD8 cells to suppress Ig synthesis but cannot provide helper
function, or respond to recall antigens . Anti-2H4(CD45RA) antibody hasbeenshown
to define the 200-kD and 220-kD isoforms of the LCA/T200 family of antigens (9),
whereas UCHL-1(CD45RO) defines the 180-kD isoform ofthis family (10, 11). Anti-
4B4(CDw29) antibody has been shown to be reactive with the VLA/integrin an-
tigen family (9, 12, 13), which is comprised of acommon (3 chain noncovalently
complexed to distinct ct chains (13, 14).
The integrin family of adhesion molecules has been shown to play an important
role in the function ofmammalian cells (15). Members of this family include CD11a-
(LFA-1), CD11b(Mol), p150-95 (16, 17), and platelet glycoprotein IIb/IIIa (18, 19),
as well as receptors for extracellular matrix proteins such as fibronectin, collagen,
and laminin (15, 20-22) . Each of the a and0 subunits of the integrin family have
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been reported to be structurally related (23-26), and many ofthesereceptors recog-
nize an Arg-Gly-Asp(RGD) sequence (21, 27). Both LFA-1 and Mol, acting as adhe-
sion structures, play an important role in lymphoid function (17).
In contrast, the functional role of fibronectin, laminin, and collagen receptors in
the immune response has yet to be established. Both a subset of murine thymocytes
and a T cell lymphoma cell have been shown to bind to fibronectin, and this binding
was inhibited by the peptide sequence Gly-Arg-Gly-Asp-Ser-Pro (28, 29). Savagner
et al. (30) have shown that invasive avian lymphocyte precursors contain inte-
grin/fibronectin receptors, and that their invasiveness could be blocked by inhibitors
of fibronectin receptor interaction. Moreover, it has been suggested that members
of the VLA/integrin family of antigens can act as fibronectin receptors on lympho-
cytes (31).
Given that our earlier studies showed that CD4+CDw29+ cells and CD4+CDw29-
cells were functionally distinct (7), we examined the role of the VLA/fibronectin
receptor family as defined by anti-4B4(CDw29) and related antibodies in CD4 T
cell function. In the present study, we show that under appropriate culture condi-
tion, a mixture of anti-CD3 antibody (32) and fibronectin can induce the activation
of CD4 cells, whereas neither alone can do it. Our studies suggest that fibronectin
may contribute to CD4 cell activation through the CD3TCR complex under physio-
logic conditions (32). In addition, anti-CDw29 (4B4) antibody blocked the activa-
tion of CD4 cells in this system. Lastly, through the use of a new antifibronectin
receptor antibody, we have shown that the VLA-5 protein acts as functionalfibronectin
receptor on CD4 cells and that this VLA-5 receptor is preferentially expressed on
the CD4+CDw29 + subset of cells and may account for the functionally unique pro-
gram of these cells.
Materials and Methods
Reagents.
￿
Human fibronectin and laminin were obtained from Collaborative Research,
Lexington, MA. Type I, III, and IV collagen from human placenta, phorbol 12-myristate,
13-acetate, L-leucine methylester, aprotinin, Cowan strain 1 bacteria, and PMSF were from
Sigma Chemical Co., St. Louis, MO. The GRGDSP peptides were from Peninsula Labora-
tories, Inc., Belmont, CA. For use in the serum-free medium, BSA, transferrin, and soybean
lipids were from Boehringer Mannheim Biochemicals, FRG. Iscove's modified Dulbecco's
medium was from Sigma Chemical Co. rIL-2 was from Biogen, Geneva, Switzerland.
Preparation of Fibronectin Fragments.
￿
Fibronectin fragments (Fig. 4, fractions A, B, C, D,
and E), the kind gift of Dr. Joyce K. Czop (Brigham and Women's Hospital, Harvard Med-
ical School, Boston, MA), were prepared as described previously (33, 34). Each of the frac-
tions was analyzed for fragments bearing fibronectin epitopes by immunoblotting using five
mouse antifibronectin mAbs (33): BC7, which recognizes an epitope within the 27,000-mol
wt NH2 terminus; CE9, which recognizes an epitope within the 18,000-mol wt link region
between the gelatin-binding and cell-adhesive domains; BD4, which recognizes an epitope
within the cell-adhesive domain; AB3, which recognizes an epitope on the a chain between
the high affinity heparin-binding domain and the interchain disulfide bonds; and CPG1, which
recognizes an epitope adjacent to the disulfide bonds near the COOH terminus. Briefly, in-
tact plasma fibronectin was isolated from the cryoprecipitate fraction of fresh, frozen, heat-
inactivated normal humanplasma by sequential chromatography on Sepharose 4B and gelatin-
Sepharose columns. Intact fibronectin was treated with chymotrypsin and chromatographed
on gelatin-Sepharose. Fraction A contains the non-gelatin-binding fragments and fraction
B contains the gelatin-binding fragments. Fraction C was prepared from a cathepsin D digest
ofintact plasma fibronectin by sequential affinity chromatography on gelatin-Sepharose, mono-
clonal CPGI anti-fibronectin-Sepharose, and monoclonal CE9 anti-fibronectin-Sepharose.MATSUYAMA ET AL.
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The non-gelatin-binding fragments that did not bind CPGl-Sepharose were eluted from CE9-
Sepharose with 0.1 M glycine-HCI, pH 2.5. Immunoblotting revealed the major protein in
fraction C to be a 130,000-mol wt fibronectin fragment bearing both the CE9 and BD4 epi-
topes. Intact fibronectin treated with cathepsin D was also sequentially chromatographed
on gelatin-Sepharose, heparin-Sepharose, and CE9-Sepharose. Fraction D contains the
non-gelatin-binding fragments eluted from heparin-Sepharose with 0.5 M NaCl; fraction
E contains the non-gelatin-binding fragments eluted from heparin-Sepharose with 0.1 M
NaCl that did not bind CE9-Sepharose. The 110,000-mol wt fibronectin cell-binding frag-
ment (fraction F) was purified as described (35). Immunoblotting confirmed that this
110,000-mol wt fragment contained the BD4 epitope but not the CE9, BC7, AB3, or CPGI
epitopes ofplasma fibronectin. The functional domain composition and fibronectin epitopes
of the major proteins in each of the fractions used in this study are summarized in Fig. 4.
Antibodies.
￿
mAbs reactive with the lymphocyte surface antigens, CD2(Tll, IgG2b), CD3
(RW24B6, IgGl; OKT3, IgG2a), CD4 (12T44D11, IgGl), CDl(T6, IgGl), CD8(21Thy 2133,
IgGl), CDlla(2F12, IgGl), CDllb(Mol, IgM), CDw29(4B4, IgGl), 8F2(IgGl), and CD45R-
(2H4, IgGl), have been previously described (4, 7, 36-38). mAb 16 was an IgG2a ofrat origin.
Full characterization ofthis antibody is described elsewhere (38a). mAb L243 directed against
common epitopes of the DR antigen was obtained from a cell clone from the American Type
Culture Collection, Rockville, MD. Goat anti-mouse Ig antibody was from Tago Inc., Bur-
lingame, CA. Anti-CD45R(2H4) and anti-CDw29(4B4) antibodies conjugated to phycoeryth-
rin were from Coulter Immunology, Hialeah, FL. Rat IgG and rabbit anti-rat Ig antibody
and FITC-conjugated rabbit anti-rat Ig antibody were fromJackson Immunoresearch, West
Grove, PA . J143 antibody (VLA-3 specific) was a gift from Dr. L. J. Old, Memorial Sloan-
Kettering Cancer Center, New York. B-5G10 antibody (VLA-4 specific) was a gift of Dr. M. E.
Hemler, Dana-Farber Cancer Institute. Anti-81`2 antibody was developed by standard hy-
bridoma technique afterimmunization ofa mouse with PHA-activated T cells from Saguinus
Oedipus. It was determined that anti-81`2 reacted with the VLA-4 protein as follows. The cx
subunit immunoprecipitated by anti-8F2 showed the same molecular weight and isoelectric
point as that immunoprecipitated by the B-5G10 antibody, which specifically recognizes the
u4 subunit of the VLA-4 molecule (14). Moreover, sequential immunoprecipitation studies
showed that both antibodies reacted with the same molecules.
Preparation ofAnti-CD3 Antibody-coatedMicrotiter Plates.
￿
100 Al of protein A-purified anti-
CD3 antibody at 100 ng/ml in 0.01 M PBS, pH 7.4, was placed in each well of a 96-well
flat-bottomed microtiter plate (3595, Costar, Cambridge, MA), which was then incubated
at room temperature for >3 h. After washing twice with PBS, the indicated amounts of ex-
tracellular matrix proteins with or without the addition ofantibodies directed against different
lymphocyte surface antigens were placed in each well and incubated at room temperature
for an additional hour.
Preparation of Cells.
￿
Human PBL were isolated from healthy donors as described previ-
ously (39). Briefly, the lymphocytes were separated into erythrocyte rosette-positive (T cells)
and -negative populations with sheep erythrocytes. The T cells were depleted ofcontaminating
monocytes by adherence to plastic plates. Further removal of monocytes from T cells was
achieved by incubation with 5 MM L-leucine methyl ester HCI. CD4' cells were obtained
by panning on anti-Ig-coated petri dishes with anti-CD8 antibody to remove CD8 cells, and
anti-CDllb and L243 antibodies to remove residual monocytes. The CD4 cells thus obtained
were >90% CD4 with <5% contamination by CD8' cells. The contamination by monocytes
was <1 in 500 cells as determined by peroxidase staining. These highly purified CD4 cells
were used for all experiments performed in this study.
Cell Culture and Proliferation Assay.
￿
CD4 cells were cultured in triplicate in anti-CD3 anti-
body-coated wells (with or without extracellular matrix proteins) at a concentration of 105
cells/well in serum-free medium consisting of Iscove MEM supplemented with 0.1% BSA,
30 Fcg/ml human transferrin, 10 p.g/ml soybean lipids, 50 A.g/mlcholesterol, 4 MM L-glutamine,
25 mM Hepes buffer (Microbiological Associates, Bethesda, MD), 0.5% sodium bicarbonate,
and 50 Rg/ml of gentamicin sulfate (Schering, Kenilworth, NJ). After 4 d in culture, each
well was labeled with 1 uCi of [3H]thymidine (ICN Radiochemicals, Irvine, CA) for 18 h.
Cells were then harvested on a PHD cell harvester (Cambridge Technology, Inc., Cambridge,
MA), and [3H]TdR incorporation was measured on a scintillation counter.1136
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Analysis ofLeukocyteItbpulations with Single-and Two-colorFluorescence Flow Cytonutry.
￿
Single-
and two-color fluorescence flow cytometric analysis was performed on an EPICSC cell sorter
(Coulter Electronics, Hialeah, FL), as described previously (39). Briefly, for single-color anal-
ysis, cells were stained with antibody 16 followed by staining with an FITC-conjugated
F(ab')2 fragment of rabbit anti-rat Ig antibody. For two-color analysis, cells stained as above
were incubated subsequently with 100 hg/ml rat Ig for 15 min. The cells were then stained
with phycoerythrin-conjugated anti-CDw29 or anti-CD45R antibodies. Control cell samples
were stained with either rat Ig followed by FITC F(ab')2 rabbit anti-rat Ig and/or isotype-
matched mouse irrelevant antibodies conjugated to phycoerythrin (Coulter Immunology).
RadiolabelingandImmunopmcipitation of Cell Surface Prokins.
￿
CD4 cells (10') or 5 x 106 cells
from other cell lines (HPB-ALL or K562) were labeled with 1 MCi of
1251 by the lactoperox-
idase technique, as described previously (40). Labeled cells were solubilized in 0.5% Triton
X-100, 10 mM Tris-HCI buffer, pH 7.4, containing 140 mM NaCI, 1 mM PMSF, and aprotinin
(10 ;4g/ml), and then precleared overnight at 4°C with 1 ml 10% (vol/vol) Staphylococcus aureus
Cowan strain 1 bacteria. The precleared lysate was then incubated at VC for 4 h with anti-
bodies coupled to Sepharose 4B beads. The antibodies, T6, 4B4, 8172, goat anti-mouse Ig,
and rabbit anti-rat Ig, were coupled to cyanogen bromide-activated Sepharose 4B (Phar-
macia Fine Chemicals, Uppsala, Sweden) at a concentration of 5 mg/ml, according to the
procedure recommended by the manufacturer. Before using for immunoprecipitation,J143
and antibody 16 were incubated with goat anti-mouse Ig and rabbit anti-rat Ig antibodies
coupled to Sepharose 4B, respectively. In preclearing experiments, 0.4 ml ofcell lysates was
precleared five times with 50 Al of 50% suspension of antibody coupled to sepharose 4B.
The immunoprecipitates were washed twice with lysis buffer, three times with 0.5% deoxy-
cholate, 10 mM Tris-HCI, 140 mM NaCl, pH 8.2, and once with 10 mM Tris-HCI, pH 8.0.
Immune complexes were analyzed under reducing or nonreducing conditions by SDS-PAGE
(6%) as described by Laemmli (41) and examined by autoradiography.
Two-dimensional GelElectrophoresis.
￿
Two-dimensional PAGE was carried out according to
O'Farrell (42). Briefly, samples were eluted from immunoprecipitates by incubation with 8 M
urea, 2% NP-40, 5% 2-ME, and 2% ampholytes (pl 3.5-10; Bio-Rad Laboratories, Rich-
mond, CA). Treated samples were applied to 4% acrylamide tube gels and subjected to IEF
for 24 h at 150 V. The gels were then equilibrated with SDS-PAGE diluent buffer containing
2-ME subjected to SDS-PAGE (6%), and then processed as described above for one-
dimensional SDS-PAGE.
Results
CD4 Cells Can Be Activated through the Combination ofAnti-CD3 Antibody andExtracel-
lularMatrix Proteins. To investigate whether extracellular matrix proteins provide
a complementary signal in the activation of CD4 cells when combined with anti-
CD3 antibody, we studied the effects ofcollagen types1, III, and IV, plasma fibronectin,
and laminin on the proliferation of highly purified CD4 cells. When purified CD4
cells were cultured with the anti-CD3 antibody in serum-free medium, there was
no proliferation above background, using antibody concentrations ofup to 5 hg/ml
(data not shown). Also, extracellular matrix proteins alone could not induce CD4
cell activation (data not shown). Utilizing this culture system, we then examined
the effect ofthe addition of the different extracellular matrix proteins combined with
the anti-CD3 antibodies on the proliferation of CD4 cells (Fig. 1). Collagen types
I, III, and IV, and fibronectin, when combined with anti-CD3 antibody, were able
to elicit the proliferation of CD4 cells. This was particularly true offibronectin, which
markedly induced CD4 cell proliferation. Laminin, even in the presence of anti-
CD3 antibody, had no effect.
Fibronectin Receptors on CD4 Cells Are Included amongtheMolecules Recognized by Anti-
4B4Antibody, andtheRGDS Sequence Is Involved in the Interaction ofFibronectin with These0
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￿
Since the above studies showed that the combination of fibronectin and
anti-CD3 was a potent activator of CD4 cells, we next focused on the interaction
between fibronectin and its receptor in CD4 activation. We examined whether the
interaction of fibronectin with an integrin receptor on CD4 cells was required for
the observed cell activation. Since anti-4B4 (CDw29) antibody has been shown to
react with the common 0 subunit bound to a number of a subunits of the VLA
integrin family (9, 12, 13), we undertook experiments to determine whether or not
anti-4134 could modulate the proliferation of CD4 cells. As shown in Fig. 2, anti-
4B4 antibody completely inhibited the proliferative response of CD4 cells activated
by anti-CD3 plus fibronectin. In contrast, anti-LFA-1 of the same isotype had no
effect. Importantly, anti-4B4 antibody did not inhibit the proliferation of CD4 cells
inducedby the combinationof anti-CD3 antibody and IL-2 or PMA. This observa-
tion suggests that anti-4114 antibody mightblocktheinteraction of fibronectin with
its receptor on CD4 cells.
Through the use of small synthetic peptides deduced from the primary structure
ofthe fibronectin cell attachment domain, the tetrapeptide Arg-Gly-Asp-Ser(RGDS)
0
x
a
U
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FIGURE 1 .
￿
Extracellularmatrixproteins canin-
duce theproliferation of CD4 cells in combina-
tion with anti-CD3 antibody. Flat-bottomed
plates were coated with anti-CD3 antibody (100
ng/ml) and/or differentextracellular matrix pro-
tein at various concentrations as indicatedin the
figure. CD4cells were cultured in theseplates in
serum-free medium for 4d, at which time pro-
liferation was assessed by determining [3H]thy-
midine incorporation. Thedata areexpressedas
the mean of triplicate samples. Each SE was
<15%. The combination of anti-CD3 antibody
andtype I, III, or IV collagen, or fibronectin in-
duced theproliferation ofCD4 cells. When flat-
bottomed plates were coated with extracellular
matrix proteins alone, [3H]thymidine incorpo-
ration was always <100cpm. Thedata shownare
representative of three separate experiments.
FIGURE 2.
￿
Anti-4134antibody inhibits theproliferationof
CD4 cells induced by the combination of anti-CD3 anti-
bodyandfibronectin. CD4cells were cultured in anti-CD3
antibody and fibronectin-coated plates, to which varying
concentrations of LFA-1 antibody (a)or 4134 antibody (d)
were added. (b andc) CD4cellswere cultured in anti-CD3
antibody-coated plates with IL-2 (100 U/ml) or PMA (1
ng/ml), respectively, and varying amountsof anti-4134an-
tibody were added to each well (dashed lines). [3H]thymidine
incorporationofCD4cells stimulated by IL-2 or PMAalone
was <1,000 cpm. CD4 cells were cultured in serum-free
medium in these plates for 4 d and the proliferation was
assessed by determining [3H]thymidine incorporation. The
data areexpressedas themeansoftriplicate samples.Each
SE was<15%. When flat-bottomedplates were coated with
fibronectin alone, the [3H]thymidine incorporation was
<100cpm.Thedata arerepresentative ofthreeseparate ex-
periments.1138
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FIGURE 3.
￿
RGDS-containingpeptide inhibits theprolif-
erationof CD4cells inducedby anti-CD3 antibody and
fibronectin. The indicated concentrations ofGRGDSP
peptide orcontrol GRGESP peptide were addedto cul-
ture wells whereCD4cells were stimulated by anti-CD3
antibody and fibronectin as described in Fig. 1. GRGDSP
peptide inhibitedtheproliferation in adose-dependent
fashion, whereas GRGESP peptide did not affect pro-
liferation. Thedata arerepresentative of three separate
experiments.
has been shown to be a crucial minimal sequence for cell attachment activity (21,
27). It synergizes with a secondary key site to mediate cell adhesion, spreading, and
cytoskeletal effects (43). To investigate the involvement of the RGDS sequence in
the interaction of fibronectin with its receptors on CD4 cells, we examined the func-
tion of this sequence in our culture system. When the hexapeptide Gly-Arg-Gly-
Asp-Ser-Pro (GRGDSP) containing the RGDS sequence was added to cell cultures,
theproliferation of CD4 cells in response to anti-CM antibody plus fibronectin was
inhibited in adose-dependent fashion, reaching 90% inhibition at amaximum con-
centration of 500 ug/ml of peptide (Fig. 3). In contrast, no inhibition was observed
with the related control hexapeptide GRGESP
Further support for the involvement of the RGDS sequence in the interaction of
fibronectin with lymphocytes was obtained by incubating the cells in anti-CM anti-
body plus proteolytic fragments of fibronectin. Fig. 4 shows the characteristics of
the variousof well-described proteolytic fragments of fibronectin used in this study.
In combination with anti-CD3 antibody, proteolytic fragments containing the cell-
adhesive domain and the high affinity heparin-binding domain (Fig. 4 A) or the
FIGURE 4.
￿
Graphic represen-
tation of the proteolytic frag-
ments of plasma fibronectin
used in this study. The major
proteins containedwithin each
of thefractionsof proteolytic fi-
bronectin fragmentsaredepicted
with their functional domains
aligned with those of the intact
molecule. The regions within
theintact molecule aresymbol-
ically shownas: NH2-terminus
domain (N-"); gelatin-binding
domain (p); 18,000-dalton link
betweenthegelatin-bindingand
cell-adhesivedomains("); cell-
adhesive domain (lam); and
high affinity heparin-binding
domain (0). A subunit chain
difference is depicted by the
asterisk above thea chain and
its derivatives. The majorpro-
teolytic fragmentsaredescribed
in termsoftheirrecognition by
five antifibronectin mAbs.
FIwdon Major Protein(s) Recognition by
BCJ CE9 BD4 A03 CPG1
Intact N + + + + +
Fibronectin N + + + - +
A + +
_ _ + _ -
C + + _ _
D =r
s
- - - + +
_ _ _ +
+
_
_
_
_
scell-adhesivedomain and the adjacent 18,000-daltonpeptide link between thegelatin-
binding and cell-adhesive domains (Fig. 4 C) caused the proliferation of CD4 cells
(Fig. 5). A mixture of proteolytic fragments consisting of the cell-adhesive domain
alone and the COOH-terminal region offibronectin containing theinterchain disulfide
bonds (Fig. 4 E) produced virtually no proliferation of CD4 cells in combination
with anti-CD3 antibody. Fragments containing the gelatin-binding domain either
aloneor attached to the 18,000-dalton link betweengelatin-binding and cell-adhesive
domains (Fig. 4 B) or fragments containing the high affinity heparin-binding do-
main alone or attached to the COOH terminus of plasma fibronectin (Fig. 4 D)
also could not produce significant proliferation of CD4 cells. In subsequent studies,
incubation with a single purified 110,000-dalton cell-adhesive domain fragment con-
tainingat leastpart ofthelink region between thecell-adhesive and the gelatin-binding
domains, but domains lackingheparin-binding sites (Fig. 4,F) plus anti-CD3 anti-
body induced half as much proliferation of CD4 cells as did incubation with intact
plasma fibronectin plus anti-CD3 antibody (average of 55% in two experiments).
Thus, the cell-adhesive region was necessary, but not fully sufficient, for maximal
proliferation.
VLA-5 Complex of the VLAIIntegrin Famity Acts as a Proliferation-associated Fibronectin
Receptor on CD4 Lymphocytes. The different proteins in the VLA family are com-
posed of one common (3 subunit and one of several different a subunits on the cell
surface of lymphocytes (14). Recently, Takada et al. (31) suggested that the VLA-3
and VLA-5 proteins might act as fibronectin receptors on lymphocytes. As shown
above, our anti-integrin anti-4B4 (CDw29) antibody blocks the activation of CD4
lymphocytesby the mixtureof anti-CD3 and fibronectin. However, immunoprecipi-
tates of anti-4134 contain common a chain and several a subunits. Thus, it is not
clear which of the subunits are actually involved in anti-CD3 fibronectin-induced
CD4cell activation. We tested anewlydevelopedratanti-human fibronectin receptor
antibody, termed antibody 16, that seems to identify on K562 cells the same struc-
tures precipitated by anti-4134 antibody. It should be notedthat K562 cellsprimarily
express the VLA-5 protein (31). In fact, neither anti VLA-3 (J143) nor anti VLA-4
(8F2) antibodies recognized any proteins from the K562 cell line (data not shown).
As shown in Fig. 6, anti-4B4 immunoprecipitated abroad band (110-130 kD) and
several a chains under both nonreducing and reducing conditions (Fig. 6, a and
60
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FIGURE 5.
￿
Proteolytic fragmentscontainingthe
cell adhesion domain of fibronectin induce the
proliferation of CD4 cells in combination with
anti-CD3 antibody. CD4 cells were cultured in
plates coated with both anti-CD3 antibody (100
nglml) and various proteolytic fragments of
fibronectin (10 pglml). After culturing for 4 d,
the proliferation was assessed by determining
[3Hithymidine incorporation by the CD4cells.
Thesevalues arethemeans t SD ofthreesepa-
rate experiments. Proteolytic fragments con-
taining a cell-adhesive domain can induce the
proliferation of CD4 cells in combination with
anti-CD3 antibody.1140
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FIGURE 6 .
￿
(a) Comparison of immunoprecipitation by anti-4114, anti-8F2, and antibody 16 .
Cell extracts of 1251-radiolabeled HPB-ALL cell line were immunoprecipitated using anti-4B4,
anti-8F2, antibody 16, J143 antibody, and rabbit anti-rat Ig antibody (lanes A, B, C, D, and
E, respectively) . Sampleswere analyzed by SDS-PAGE (6% polyacrylamide) under nonreducing
conditions . (b) Preclearing analysis ofcell extracts of 1211-radiolabeled HPB-ALL cell line by anti-
4B4 and antibody 16 . Cell extracts were precleared with the control antibody antiT6, antibody
16 (rat 16), and anti-4114, (lanes A-D;E-H; and I-L, respectively). Cell extracts from the HPB-
ALL cell line were immunoprecipitated with anti-4114, 8F2, 16, and J143 antibodies, (lanes A,
E,1; B, F,J ; C, G,K; andD, H, I, respectively) . Reduced samples were analyzed by SDS-PAGE
(6% polycrylamide) .
b, lanesA andB), respectively, from theHPB-ALL cell line. AntiVLA-4 (8F2) im-
munoprecipitated 110-kD (3 and 140-kDa (Fig. 6 a, and lane B) undernonreducing
conditions and 130-kD 0 and 150-kD a subunits (Fig . 6 b, lane B) under reducing
conditions . Although the ci chain recognized by antibody 16 (Fig . 6 a, lane C) is
similar in mobility under nonreducing conditions to the a subunit recognized by
theJ143 antibody (VLA3) (Fig. 6 a, lane D), underreducing conditions, thea subunit
recognized by antibody 16 has a higher molecular weight than that recognized by
the antiVLA-3 antibody (Fig . 6 b, lanes C and D) .
Furthermore, when cell lysates from theHPB-ALLwere incubated with antibody
16, the proteins recognized by J143 antibody (VLA-3) were not cleared (Fig. 6 b,
lane H) . However, incubation of cell lysates with anti-4B4 antibody precleared the
protein recognized by bothJ143 and 16 antibodies (Fig. 6 b, lanesKandL) . Further
evidence that antibody 16 does not crossreact with the VLA-3 tx subunit was ob-
tained from two-dimensional gel analysis . Thea subunit from HPB-ALLcells rec-
ognized by antibody 16 had amore acidic isoelectric point than the a subunit (Fig .
7 A), while theVLA-3 a subunit recognized by J143 antibody has a more basic iso-
electric point than the a subunit (Fig . 7 B) . Similarly, when antibody 16 was used
to immunoprecipitate cell lysates from the K562 cell line, the tx chain once again
was more acidic than the a chain (Fig . 7 D) . Thus, the proteins recognized by anti-
body 16 are different from VLA-4 (Fig . 7 C)andVLA-3 (Fig . 7 B) . Finally, antibody16 did notcrossreact with the ot subunit oftheVLA-1 andVLA-2 proteins that have
been shown to be expressedon activatedTlymphocytes(datanotshown). The above
results indicate that antibody 16 is specific for the VLA-5 protein .
We used these mAbs to investigate which members of theVLA family within the
4B4 molecules are actually involved in the synergistic activation of CD4 cells by
anti-CD3 andfibronectin . Asshownin Fig. 8, antibody 16, like anti-4134, wasunique
.o-. .. .....-.o~ ...-. ..o
o---- e
.. .. . .. .. .
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FIGURE 7 . Two-dimensional
gel analysis ofimmunoprecipi-
tates by 16, 8F2, andJ143 anti-
body using the HPB-ALL cell
line. 1211-radiolabeled cell ex-
tract from HPB-ALL cells was
immunoprecipitated with anti-
body 16 (A),J143 antibody (B),
and8F2 antibody (C). An 125I-
radiolabeled cell extract of the
K562 cell line was immunopre-
cipitated with antibody 16 (D).
achainsofthe immunoprecipi-
tates with antibody 16 from
HPB-ALL and the K562 cell
line migrated to a more acidic
point than the /3 chain, whereas
those immunoprecipitated by
J143 and 8F2 antibodies mi-
grated to a point more basic
than the S chain .
FIGURE 8 .
￿
Antibody 16 inhibits the proliferation ofCD4
cells induced by the combination ofanti-CD3 antibody and
fibronectin . (a and d)CD4 cells were cultured in anti-CD3
antibody and fibronectin-coated plates . (b and c)CD4 cells
were cultured in anti-CD3 antibody-coated plates with IL2
(100 U/ml) orPMA (1 ng/ml), respectively. [3H]Thymidine
incorporation ofCD4 cells stimulated by IL-2 orPMAalone
was<1,000cpm . Open circles represent the amounts ofan-
tibody 16 and closed circles represent the amounts ofLEA
1 antibody used in this experiment . CD4 cellswere cultured
in serum-free medium in these plates for 4 d, after which
proliferation was assessed by determining [3H]thymidine
incorporation.Thedataare expressed as themean oftripli-
cate samples . Each SE was <15% . When flat-bottomed
plates were coated with fibronectin alone, <100 cpm of
[3H]thymidine incorporation was obtained . Antibody 16
antibody inhibits the proliferation ofCD4 cells induced by
anti-CD3 antibody and fibronectin but not the prolifera-
tion ofCD4 cells induced by anti-CD3 antibody and IL-2
orPMA . The data are representative ofthree separate ex-
periments.1142
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FIGURE 9. The relationship
between antibody 16 antigen
(VLA-5) and 2114 and 4114anti-
gens on CD4 cells . Two-color
cytofluorographic analysis of
CD4 cells with anti-4134 anti-
body or anti-2114 antibody con-
jugated to phycoerythrin, and
antibody 16 (followed by FITC
anti-rat Ig antibody) was per-
formed on a logarithmic scale.
Fluorescence intensities of4134,
or 2114, and 16 antigen are ex-
pressed on the x- andy-axis, re-
spectively. They-axis shows cell
number. The data are represen-
tative of six separate experi-
ments using CD4 cells from
different healthy donors .
in its ability to inhibit the proliferation of CD4 cells in the presence of anti-CD3
antibody plus fibronectin . In contrast, the control antibody LFA-1 hadno inhibitory
activity. Moreover, antiVLA-3 and antiVLA-4 antibodies were also unable to in-
hibit anti-CD3 plus fibronectin-induced CD4 cell proliferation (data not shown) .
The above finding indicates that the VLA-5 protein acts as a fibronectin receptor
on theCD4lymphocytes and that this receptor-ligand interaction is of great impor-
tance to lymphocyte activation in this system . It should be noted that antibody 16
did not inhibit the activation ofCD4 cells in the presence of anti-CD3 plus type
I, III, or IV collagen, whereasanti-4134 antibody could inhibittheseresponses (data
not shown) . However, as shown in Fig . 1, the proliferation ofCD4 cells in the pres-
ence of anti-CD3 and type I, III, or IV collagen is significantly lower than that in-
duced by anti-CD3 and fibronectin . Taken together, these results suggest that it is
within the setof molecules recognized by anti-4114 that is of key importance to lym-
phocyte activation in this system .
The Distribution of 16 Antigen (VLA-5) on Subsets ofCD4 Cells .
￿
Next, the relation-
ship between 16 antigen (VLA-5) and the 2114 and 4134 antigens on CD4 cells was
determined by using double fluorescence staining . As shown in the representative
experiment in Fig . 9, the majority of cells expressingVLA-5 antigen also expressed
the 4134 antigen (90%). In contrast, only 15% of the cells expressing the VLA-5
antigen coexpressed the 2114 antigen . Furthermore, only low density 2114 cells coex-
pressed the VLA-5 antigen . It should be noted that few, if any, CD4 cells expressed
both 2114 and VLA-5 at high antigen density. These studies further support the
notion that the differential expression of the VLA-5 on distinct CD4 subsets may
contribute to the previously defined functional differences between the CD4'4B4+
and CD4'2H4+ subsets (4, 7, 8) .
Discussion
In the present study, we have demonstrated that fibronectin synergizes with anti-
C133 antibody in the activation ofCD4 cells . Furthermore, ourstudies showed that
the minimal fibronectin recognition sequence, RGDS (21, 27, 44), could block thisMATSUYAMA ET AL.
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activation, and fragments of the fibronectin molecule containing the cell adhesive
domain plus additional regions are required for this synergistic effect. The ability
offibronectin plus anti-CD3 antibody to induce CD4cell activation couldbe blocked
by anti-4B4 (CDW29), an anti-class 1(3 integrin antibody. Moreover, we determined
that anti-4B4 recognizes aset ofVLA-5 heterodimers that can function as afibronectin
receptor on the CD4 lymphocytes. The fibronectinVLA-5 interaction may be of
substantial importance in lymphocyte activation.
In preliminary studies, we attempted to identify extracellular matrix protein
receptors on CD4 lymphocytes by enriching for cells selectively bound to specific
extracellular matrix proteins, including laminin, fibronectin, and collagen. How-
ever, using fibronectin-coated plates, we were only able to partially enrich forbound
CD4 cells (data not shown). In the studies reported above, we developed a more
sensitiveassay system for thecharacterization of extracellular matrix protein receptors
on CD4 cells. Since a number of matrix proteins are present in serum, and mono-
cytescanproducefibronectin (45), ourassaysystem relies on the use of highly purified
CD4 cells in serum-free media. In this system, a mixture of anti-CD3 antibody and
fibronectin could induce CD4 cellular activation, whereas neither could do it alone.
This synergistic effect of fibronectin with anti-CD3 antibody on CD4 prolifera-
tion appears to be specific since crosslinking of anti-CD3 antibody to other anti-
bodies directed toward cell surface structures, such as CD4, class I, CD45R, and
CD11a, did not induce proliferation in this system (data not shown). Second, en-
hanced proliferation can also be seen when soluble fibronectin is added to anti-CD3-
coated plates that have been saturated with BSA to reduce nonspecific interactions
between anti-CD3 and fibronectin (data not shown). These studies, as well as those
presented above, suggested that binding of fibronectin to its receptor on CD4 cells
may induce activation through the CD3TCR complex. How this CD4 cell activa-
tion occurs is not entirely clear, but onepiece ofevidence presentedabove, that RGDS
containing peptides and fibronectin fragments and anti-4B4, as well as anti-human
fibronectin receptor (VLA-5) antibodies, block fibronectin-induced proliferation,
suggests an important role for the fibronectin receptor in T cell activation.
A costimulatory effect of fibronectin on another type of cell activation has been
observed in monocytes. Binding of fibronectin to its receptor on monocytes and
costimulation with either C3b or IgG generates a signal that enhances phagocytosis
ofopsonizedparticles(46). Moreover, the 180-kD opsonic fibronectin fragment (180-kD
opFnf), which has been purified from normal human plasma, augments monocyte
phagocytosis of particulate activators ofthe human alternative complement pathway
without affecting IgG- or C3b-mediated functions (34). The mechanism by which
fibronectin enhances these cell functions is still not fully understood. It has been
suggested that theinteraction of fibronectin to itsreceptor mightactivate cellsthrough
the phosphorylation of a tyrosine residue on the VLA/integrin antigen family of
/3 chain (47, 48), and other surface receptors containing phosphorylated tyrosine
residues are known to be related to cell activation and cell growth (49).
In our studies, laminin had no effect on the proliferation of CD4 cells, whereas
type I, III, and IV collagen had a modest effect compared with fibronectin (Fig.
1). Tomaselli et al. (50) reported that the receptor for laminin and type IV collagen
on a rat neuronal cell line was likely to be VLA-1 and/or VLA-3 proteins, whereas
the laminin receptor on platelets was reported to be VLA-6 (51). Others (14, 52)1144
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have shown that VLA-2 can be a collagen receptor on leucocytes and other cells.
In our studies, anti-4B4 (CDW29) antibody blocked the CD3-induced activation
of CD4 cells with fibronectin as well as type I, III, or IV collagen. Antibody 16,
in contrast, inhibited only CD4 cell activation when anti-CD3 was combined with
fibronectin but had no effect in the presence of type I, III, or IV collagen. Results
presentedhere strongly suggest that antibody 16 is directed toward the VLA-5 pro-
tein a subunit and that it only inhibited cell activation on anti-CD3 combined with
fibronectin. Thus, fibronectin appears to interact with CD4 cells through the VLA-
5 protein and synergizes with anti-CD3 antibody in the activation of CD4 cells.
Antibody 16 recognizes a subset ofthe molecules reactive to anti-4B4. Thus, although
anti-4B4 and antibody 16 appear to have similar distributions on CD4 and K562
cells, a small percentage of 4B4'16- and 16+4B4- cells do exist. In this regard, more
recently Wayner et al. (53) have also described mAbs that specifically inhibit the
adhesion of human cells to fibronectin, but not collagen or laminin. Moreover, the
molecules recognized by theseantibodies were shown to be identical to the fibronectin
receptor and VLA-5.
The RGDS sequence contained within the fibronectin cell-adhesive domain ap-
pears to be involved in this synergistic activation of CD4 cells by anti-CD3. How-
ever, fragments containing the cell-adhesive domain alone were unable to induce
the same degree of CD4 cell proliferation as that induced by intact fibronectin. This
result suggests that additional regions ofthe fibronectin molecule outsideofthe cell-
adhesive domain are also involved in the activation of CD4 cells. One possibility
is that the other regions of the fibronectin molecule are required to stabilize the
tertiary structure of the cell-adhesive domain, allowing its optimal binding to CD4
cells. Alternatively, these additional regions of the fibronectin molecule may them-
selves be required for maximal receptor-ligand interaction or crosslinking and sub-
sequent cell activation. Further mutational analysis of fibronectin mayhelp to clarify
whether the presence of other fibronectin regions increases the efficiency ofbinding
of the cell-adhesive domain to the fibronectin receptor or to the cell surface as a
whole and how this is translated into an increase in CD4 cell activation detected
by our culture system.
It has been suggested that fibronectin receptorshave arole in anchorage andmigra-
tion of various types of cells during maturation. Early lymphoid cells express the
fibronectin receptor that mayplay a role in thymic colonization (30) and Bcell differen-
tiation (54). Moreover, it has been reported that the murine thymocytes that bind
specifically to fibronectin are cortical thymocytes, suggesting that the fibronectin
receptor on thymocytes is important in Tcell differentiation (28). Similarly, erythroid
differentiation is associated with a loss of cell adhesion to fibronectin, which corre-
lates with aloss of fibronectin receptor expression (55). In addition to the positional
rolesof fibronectin receptors on variouscells, ourresults indicate that the fibronectin
receptor on CD4 lymphocytes with interaction of fibronectin may play some roles
in lymphocyte activation and growth.
The fibronectin receptor (VLA-5) is also preferentially expressed on a subset of
mature CDW29(4B4)+CD45R- cells. The subset of CD4 mature cells responds
maximally to soluble antigens in the presence of self MHC class II-bearing mono-
cytesand provides good helper function for B cell Ig synthesis(7). Thepresentresults
might explain the preferential response of CD4+CDw29+ cells to soluble antigens,MATSUYAMA ET AL.
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since the fibronectin receptor is involved in this unique function of this CD4 subset
by augmenting activation through the CD3TCR complex. In addition, it may ex-
plain the maximal signals for B cell help generated by this subset by augmenting
cell interaction with B cells through fibronectin or other integrin family adhesive
receptors. That monocytes produce fibronectin suggests that physiologic augmenta-
tion ofantigen-specific T cell activation by fibronectin might occur when CD4 cells
and monocytes interact, as well as in cases where antigens are presented in associa-
tion with extracellular matrix proteins.
Summary
In this study, fibronectin synergized with anti-CD3 antibody to promote CD4
cell proliferation in a serum-free culture system. The cell-adhesive domain plus ad-
ditional regions of the fibronectin molecule are involved in this synergy. Anti-
4B4(CDw29) antibody blocked the activation of CD4 cells in this system. Further-
more, it is the VLA-5 protein within the set of molecules recognized by anti-4B4
that serves as a fibronectin receptor on the CD4 lymphocytes. The VLA-5 fibro-
nectin receptor was mainly expressed on CD4+ CD45R-CDw29+ cells and may in
part contribute to the unique function of these cells.
Receivedforpublication 12 April 1989 and in revisedform 13 June 1989.
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